

Actigraphic assessment of sleep quality in the A4 trial

<https://neurodegenerationresearch.eu/survey/actigraphic-assessment-of-sleep-quality-in-the-a4-trial/>

Principal Investigators

ROSENBERG, PAUL B.

Institution

JOHNS HOPKINS UNIVERSITY

Contact information of lead PI

Country

USA

Title of project or programme

Actigraphic assessment of sleep quality in the A4 trial

Source of funding information

NIH (NIA)

Total sum awarded (Euro)

€ 1,535,335.78

Start date of award

15/07/2015

Total duration of award in years

2

The project/programme is most relevant to:

Alzheimer's disease & other dementias

Keywords

Acquired Cognitive Impairment... Aging... Alzheimer's Disease... Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)... Brain Disorders... Clinical Research... Clinical Research - Extramural... Dementia... Neurodegenerative... Neurosciences... Prevention... Sleep Research... Translational Research

Research Abstract

? DESCRIPTION (provided by applicant): The Anti-Amyloid Treatment of Asymptomatic Alzheimer's Disease (A4) parent trial is a trial of anti-amyloid therapy for prevention of cognitive decline in 1000 participants who are cognitively healthy, 65-85 years old, and have evidence of amyloid in their brain on flobetapir PET scans. Quality of sleep is important for quality of life and there is evidence for poorer sleep quality in older persons and in persons at risk of developing Alzheimer's disease. Actigraphy is a low-cost noninvasive method of measuring activity validated for assessing sleep quality, using an accelerometer that is worn like a wristwatch. We propose to add actigraphic assessment of sleep quality in 50 amyloid-positive and 50 amyloid-negative participants who have consented to A4. We hope to assess the effect of anti-amyloid therapy on sleep quality, and the effect of baseline amyloid status on changes in sleep in the placebo and amyloid-negative group.

Lay Summary

PUBLIC HEALTH RELEVANCE: Sleep is important to quality of life and may also reflect underlying brain processes of aging. We propose to add a low-cost noninvasive measure of sleep (actigraphy) to the Anti-Amyloid Treatment of Asymptomatic Alzheimer's Disease Trial (A4) to better understand sleep as an outcome for prevention of functional decline in aging.

Further information available at:

Types:

Investments > €500k

Member States:

United States of America

Diseases:

Alzheimer's disease & other dementias

Years:

2016

Database Categories:

N/A

Database Tags:

N/A